Hypothyroidism News and Research

RSS

Hypothyroidism occurs when the thyroid gland does not produce enough thyroid hormone to meet the body’s needs. Without enough thyroid hormone, many of the body’s functions slow down. About 5 percent of the U.S. population has hypothyroidism. Women are much more likely than men to develop hypothyroidism.

Novartis' Tasigna capsules meets primary endpoint in comparison trial with Gleevec

Novartis announced today that Tasigna (nilotinib) 200 mg capsules met its primary endpoint in the first head-to-head comparison with the company's groundbreaking drug Gleevec (imatinib mesylate) tablets*. Tasigna produced faster and deeper responses than Gleevec when given as first-line therapy for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. Tasigna was well tolerated in the study.

20 Oct 2009

Schering-Plough to present data on boceprevir at the AASLD 2009 Annual Meeting

Schering-Plough announced that data on boceprevir, an investigational hepatitis C virus (HCV) protease inhibitor, will be reported in an oral presentation at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting in Boston, Oct. 30-Nov. 3.

19 Oct 2009

AstraZeneca's CRESTOR approved for treating pediatric patients with HeFH

AstraZeneca today announced the U.S. Food and Drug Administration (FDA) approved CRESTOR® (rosuvastatin calcium) for use in pediatric patients ages 10-17 with heterozygous familial hypercholesterolemia (HeFH) when diet therapy fails to reduce elevated cholesterol. HeFH, a genetic disease, is characterized by high LDL cholesterol (the "bad" cholesterol) and increased risk of early cardiovascular disease.

19 Oct 2009

9% of Québec adults report being diagnosed with a thyroid disease

New research reveals 9 percent of Québec adults report being diagnosed with a thyroid disease. The thyroid gland produces the hormones that regulate our growth, maturation, speed of metabolism and sensitivity to other hormones.

13 Oct 2009

Schering-Plough receives FDA recommendation approval for PEGINTRON

Schering-Plough Corp. announced that the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) recommended approval by a vote of six to four for PEGINTRON® (pegylated interferon alfa-2b) in the adjuvant treatment of patients with Stage III malignant melanoma.

6 Oct 2009

King Pharmaceuticals achieves milestone: Announces commercial availability of EMBEDA

King Pharmaceuticals(R), Inc. (NYSE: KG) today announced a true milestone as it marks the first commercial availability for EMBEDA(TM) (morphine sulfate and naltrexone hydrochloride) Extended Release Capsules, a long-acting Schedule II opioid analgesic for the management of moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time.

21 Sep 2009

Study reveals that KCNE2 and KCNQ1 mutations can results in thyroid dysfunction

Genes previously known to be essential to the coordinated, rhythmic electrical activity of cardiac muscle -- a healthy heartbeat -- have now also been found to play a key role in thyroid hormone (TH) biosynthesis, according to Weill Cornell Medical College researchers.

21 Sep 2009

Forest Laboratories places Armour Thyroid medication on back order

Forest Laboratories, Inc., the maker of the widely used hormone therapy drug, Armour® Thyroid, recently announced it has placed the medication on back order. The company said on its website that it does not have enough of the active ingredient, powdered Thyroid gland, in stock to produce the medication.

15 Sep 2009

Giant pituitary adenoma can be safely removed through nasal route

It’s even worse than being told you have a brain tumor: having a tumor so large, it’s in a category all its own. Giant pituitary adenoma is a so-called “benign” tumor that can cause visual loss and impair many of the body’s most basic functions. But fortunately, even the largest of these giant tumors—which can grow to the size of an egg and invade nearby structures--can be treated effectively using a multimodality approach starting with minimally invasive surgery through the nose, according to a new study at the John Wayne Cancer Institute at Saint John’s Health Center.

12 Aug 2009

Women with a history of hypothyroidism at greater risk of developing liver cancer

Women with a history of hypothyroidism face a significantly higher risk of developing liver cancer, according to a new study in the May issue of Hepatology, a journal published by John Wiley & Sons on behalf of the American Association for the Study of Liver Diseases (AASLD). The article is also available online at Wiley Interscience.

4 May 2009

Food giant Unilever on a worthy mission to reduce salt in all products

The Anglo-Dutch food giant Unilever has announced plans to reduce the amount of salt in almost all its 22,000 food products - Unilever says its efforts to establish comprehensive salt reduction targets will help improve public health and are a first worldwide.

22 Apr 2009

Concern over inappropriate diagnosis and treatment of primary hypothyroidism

More and more people are being inappropriately diagnosed and treated for underactivity of the thyroid gland (known as primary hypothyroidism), warn doctors in an editorial published on bmj.com today.

29 Mar 2009

Crestor (rosuvastatin calcium) shown to significantly reduce major cardiovascular events

New data from the JUPITER study demonstrated that Crestor (rosuvastatin calcium) 20 mg significantly reduced major cardiovascular (CV) events (defined in this study as the combined risk of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from CV causes) by a dramatic 44% compared to placebo (p<0.001) among men and women with elevated hsCRP but low to normal cholesterol levels.

10 Nov 2008

Premature babies feel pain but don't show it

Brain scans of premature babies undergoing a simple medical procedure have revealed though they may appear to be pain free, they are experiencing pain.

24 Jun 2008

Subclinical hypothyroidism common in chronic kidney disease

Many patients with chronic kidney disease (CKD) have mild reductions in thyroid function, or subclinical hypothyroidism-a condition that becomes more common as kidney function declines, according to a study in the September 2008 issue of Clinical Journal of the American Society of Nephrology (CJASN).

11 Jun 2008

Novel newborn screening kits developed by NovaUCD-based Enzolve Technologies

Enzolve Technologies, a UCD spin-out company based at NovaUCD the Innovation and Technology Transfer Centre at University College Dublin, has received substantial investment from Enterprise Ireland under the National Development Plan (2007-2013) and private investors.

29 Apr 2008

Cardiovascular and metabolic issues in patients with thyroid dysfunction

Thyroid experts will present the latest information on cardiovascular and metabolic issues in patients with thyroid disorders, including those who have an underactive thyroid (hypothyroidism) or an overactive thyroid (hyperthyroidism), at a day-long scientific meeting on Friday, March 28, 2008 at the Marriott Metro Center in Washington, DC.

26 Mar 2008

Hypothyroidism treatment no 'quick fix' for weight loss in children

Children treated for hypothyroidism aren't likely to drop pounds with treatment for the condition says a new study in the Journal of Pediatrics.

4 Jan 2008

Even mildly underactive thyroid doubles risk of heart conditions

Individuals with subclinical hypothyroidism - a mildly underactive thyroid only detectable by a blood test - are twice as likely to develop heart failure, compared to those with normal thyroid levels, according to a new study presented on Thursday, Oct. 4, at the 78th Annual Meeting of the American Thyroid Association (ATA) in New York.

4 Oct 2007

FDA tightens potency specifications to ensure thyroid drugs last

The U.S. Food and Drug Administration is tightening the potency specifications for levothyroxine sodium, used to treat underactive thyroid glands and other thyroid conditions, to ensure the drug retains its potency over its entire shelf life.

4 Oct 2007